Improving breast cancer treatment by targeting a specific enzyme to enhance drug effectiveness
Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors
This study is looking at how a specific enzyme called PFKFB3 affects the way some patients with advanced hormone receptor-positive breast cancer respond to certain treatments, with the hope of finding better ways to help these patients get the most out of their therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10872259 on NIH RePORTER |
What this research studies
This research investigates how the enzyme 6-phosphofructo-2-kinase (PFKFB3) contributes to resistance against CDK4/6 inhibitors in patients with stage IV hormone receptor-positive breast cancer. By understanding the role of PFKFB3 in cancer cell metabolism, the researchers aim to develop new strategies that could enhance the effectiveness of existing treatments. The study involves laboratory experiments and analysis of patient tumor samples to identify how PFKFB3 activity changes in response to treatment. Ultimately, the goal is to find ways to overcome treatment resistance and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with stage IV hormone receptor-positive breast cancer who are currently receiving or have received CDK4/6 inhibitors.
Not a fit: Patients with early-stage breast cancer or those who do not have hormone receptor-positive breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced breast cancer, potentially prolonging survival and improving quality of life.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach may also yield beneficial outcomes.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Imbert-Fernandez, Yoannis — University of Louisville
- Study coordinator: Imbert-Fernandez, Yoannis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.